French study shows benefits of Biofield's BBE
This article was originally published in Clinica
Executive Summary
Results of a French study using Biofield's (US) BBE breast cancer detection device show it can outperform conventional mammography. Prof Lamarque (Montpellier) and Dr Vanel (Paris), who presented their results at the Journees Francaises de Radiologie '95 in Paris last week, showed the non-invasive device has a sensitivity of 92% and specificity of 59%. Some 119 BBE tests were carried out on 66 benign and 53 malignant lesions, giving a negative predictive value of 91% and positive predictive value of 65%. This compares favourably with mammography which is estimated to have a sensitivity of 85%-90% and a specificity of 20-40%.